Effects of the Tight Junction Protein CLDN6 on Cell Migration and Invasion in High-Grade Meningioma

Yang, Anqiang; Yang, Xiaobin; Wang, Jianqiu; Wang, Xiaojun; Wu, Hegang; Fan, Li; Li, Hao; Li, Jiangtao

doi:10.1016/j.wneu.2021.04.005

Cited by 8 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liposomes have been successfully used for the delivery of transgenes to different CNS cells in different CNS disease models (Table 2–5) including gliomas, [ 47 ] Alzheimer's, [ 48 ] Parkinson's disease, [48a,49] HIV, [ 50 ] and meningiomas. [ 51 ] For SCI studies carried out in vitro, the most commonly used lipid‐based carriers for neuronal transfection are the Invitrogen Lipofectamine products. Lipofectamine 2000 has been used to deliver multiple types of transgenes to both cell line (PC12, [ 52 ] SHSY‐5Y, [ 53 ] VSC4.1, [ 54 ] Neuro2A, [ 55 ] NSC‐34, [ 56 ] C6, [ 57 ] IOMM‐Lee, [51b,58] CH157‐MN) [51b,58b] and primary neurons, astrocytes, and CNS fibroblasts [58b,59]…”

Section: Advances In Biomaterials Vectors and Nonviral Gene Delivery ...mentioning

confidence: 99%

“…[ 51 ] For SCI studies carried out in vitro, the most commonly used lipid‐based carriers for neuronal transfection are the Invitrogen Lipofectamine products. Lipofectamine 2000 has been used to deliver multiple types of transgenes to both cell line (PC12, [ 52 ] SHSY‐5Y, [ 53 ] VSC4.1, [ 54 ] Neuro2A, [ 55 ] NSC‐34, [ 56 ] C6, [ 57 ] IOMM‐Lee, [51b,58] CH157‐MN) [51b,58b] and primary neurons, astrocytes, and CNS fibroblasts [58b,59]…”

Section: Advances In Biomaterials Vectors and Nonviral Gene Delivery ...mentioning

confidence: 99%

See 1 more Smart Citation

Biomaterial‐Based Gene Delivery to Central Nervous System Cells for the Treatment of Spinal Cord Injury

McGuire,

Stasiewicz,

Woods

et al. 2023

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Spinal cord injury (SCI) is a devastating traumatic injury often causing permanent loss of function. The challenge of treating SCI stems from the development of a complex pathophysiology at the site of injury, involving multiple biochemical cascades, widespread inflammation, blood supply interruption, inhibitory scar formation, and poor regrowth of injured axons. Clinical options are limited to surgical stabilization and attempt to ameliorate secondary damage following injury. Gene therapy has significant potential to tackle multiple aspects of SCI and improve functional outcomes. The emergence of a diverse array of biomaterial‐based nonviral nanoparticle vectors capable of delivering gene‐modifying nucleic acids offers the potential to improve the efficiency and specificity of genetic cargos for spinal cord regeneration. In this review, the progress that has been made in the field of SCI repair and the different types of nanoparticles and nucleic acid cargoes that have been used are outlined, placing a particular focus on the different cell types and pathways targeted. While many challenges remain, a perspective on the future of the field of nanoparticle‐mediated gene delivery for SCI is provided, including using biomaterial scaffolds engineered specifically for SCI to deliver gene therapeutics and the exciting opportunities that exist in the post‐COVID landscape.

show abstract

Section: Advances In Biomaterials Vectors and Nonviral Gene Delivery ...mentioning

confidence: 99%

Section: Advances In Biomaterials Vectors and Nonviral Gene Delivery ...mentioning

confidence: 99%

Biomaterial‐Based Gene Delivery to Central Nervous System Cells for the Treatment of Spinal Cord Injury

McGuire,

Stasiewicz,

Woods

et al. 2023

Advanced NanoBiomed Research

View full text Add to dashboard Cite

show abstract

“…The downregulation of CLND6 has been associated with tumor occurrence, and its overexpression accelerates apoptosis in cancer cells ( 84 – 87 ). Additionally, CLND6 has been found to regulate migration and invasion capacities in malignant meningioma cell models ( 88 ). Rat sarcoma (RAS) is a member of the small GTPase family that participates in the regulation of embryonic development, differentiation, cell-cycle progression, and cell survival ( 89 ).…”

Section: Resistance To Apoptosismentioning

confidence: 99%

“…Rat sarcoma (RAS) is a member of the small GTPase family that participates in the regulation of embryonic development, differentiation, cell-cycle progression, and cell survival ( 89 ). The downregulation of RAS activity leads to significantly reduced ERK and AKT phosphorylation, suppresses proliferation, and induces the apoptosis of human meningioma cells ( 88 ). Furthermore, let-7d, a member of the let-7 family, has been regarded as a tumor suppressor in various cancers ( 90 – 92 ).…”

Section: Resistance To Apoptosismentioning

confidence: 99%

Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature

Peng

Yuan

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Meningiomas, the most frequent primary intracranial tumors of the central nervous system in adults, originate from the meninges and meningeal spaces. Surgical resection and adjuvant radiation are considered the preferred treatment options. Although most meningiomas are benign and slow-growing, some patients suffer from tumor recurrence and disease progression, eventually resulting in poorer clinical outcomes, including malignant transformation and death. It is thus crucial to identify these “high-risk” tumors early; this requires an in-depth understanding of the molecular and genetic alterations, thereby providing a theoretical foundation for establishing personalized and precise treatment in the future. Here, we review the most up-to-date knowledge of the cellular biological alterations involved in the progression of meningiomas, including cell proliferation, neo-angiogenesis, inhibition of apoptosis, and immunogenicity. Focused genetic alterations, including chromosomal abnormalities and DNA methylation patterns, are summarized and discussed in detail. We also present latest therapeutic targets and clinical trials for meningiomas' treatment. A further understanding of cellular biological and genetic alterations will provide new prospects for the accurate screening and treatment of recurrent and progressive meningiomas.

show abstract

“…Studies have shown that CLDN6 inhibits the development and progression in some cancers such as breast cancer [22,24,[61][62][63], cervical cancer [56], and meningioma [64]. In hepatocellular cancer [50,65,66], gastric cancer [52,67], endometrial cancer [68,69], and ovarian cancer [70], CLDN6 has the opposite roles.…”

Section: The Malignant Phenotypes Of Cldn6 Affected In Cancersmentioning

confidence: 99%

CLDN6: From Traditional Barrier Function to Emerging Roles in Cancers

Qiu

Quan

2021

IJMS

View full text Add to dashboard Cite

Claudins (CLDNs) are the most important tight junction proteins, which are mainly expressed in endothelial cells or epithelial cells in a tissue-specific manner. As a member of the CLDNs family, CLDN6 is highly expressed in fetal tissues such as the stomach, pancreas, lung, and kidney, but is not expressed in corresponding adult tissues. The expression of CLDN6 is regulated by a variety of factors, including but not limited to stimuli and transcription factors, DNA methylation, and post-translational modifications. CLDN6 has been found to have a key role in the formation of barriers, especially the lung epithelial barrier and the epidermal permeability barrier (EPB). Importantly, the roles of CLDN6 in cancers have gained focus and are being investigated in recent years. Strong evidence indicates that the altered expression of CLDN6 is linked to the development of various cancers. Malignant phenotypes of tumors affected by CLDN6 include proliferation and apoptosis, migration and invasion, and drug resistance, which are regulated by CLDN6-mediated key signaling pathways. Given the important role in tumors and its low or no expression in normal tissues, CLDN6 is an ideal target for tumor therapy. This review aims to provide an overview of the structure and regulation of CLDN6, and its traditional barrier function, with a special emphasis on its emerging roles in cancers, including its impact on the malignant phenotypes, signal-modulating effects, the prognosis of tumor patients, and clinical applications in cancers.

show abstract

Effects of the Tight Junction Protein CLDN6 on Cell Migration and Invasion in High-Grade Meningioma

Cited by 8 publications

References 29 publications

Biomaterial‐Based Gene Delivery to Central Nervous System Cells for the Treatment of Spinal Cord Injury

Biomaterial‐Based Gene Delivery to Central Nervous System Cells for the Treatment of Spinal Cord Injury

Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature

CLDN6: From Traditional Barrier Function to Emerging Roles in Cancers

Contact Info

Product

Resources

About